HOME >> BIOLOGY >> NEWS
Identifying genes that contribute to a low level of response to alcohol

  • A low level of response (LR) to alcohol is predictive of future risk of alcoholism.
  • Previous research has found that a low LR has a heritability as high as 60 percent, which implies a genetic link.
  • A review of previous research has identified several categories of genes of potential interest.

Alcoholism is a complex, genetically influenced disorder. Multiple phenotypes measurable and/or observable traits or behavior contribute to the risk of developing alcoholism, particularly disinhibition, alcohol metabolizing patterns, and a low level of response (LR) to alcohol. A low LR to alcohol seems to be particularly relevant, with data indicating that LR relates to risk status, predicts future alcoholism, and has a heritability as high as 60 percent. A review in the October issue of Alcoholism: Clinical & Experimental Research examines previous research, seeking to identify those genes that may contribute to a low LR to alcohol.

"Prospective studies have shown that a low response to alcohol absolutely does increase your risk for future alcohol-related problems, at least in part by changing your expectations of what it is that you expect during drinking," said Marc A. Schuckit, director of the Alcohol Research Center, Veterans Affairs San Diego Healthcare System, professor of psychiatry at the University of California, San Diego, and first author of the study.

"However," Schuckit added, "the key is that people drink especially early in their careers for effect, which often means intoxication. An individual who experiences not much of an effect from alcohol will still feel effects like anybody else, but they'll just require more to do it, and this will probably impact their expectations of what alcohol is going to do for them."

"Different people have a different initial response to alcohol, also known as level of sensitivity," said David Goldman, chief of the Laboratory of Neurogenetics at the
'"/>


14-Oct-2004


Page: 1 2 3

Related biology news :

1. Identifying the mechanism behind a genetic susceptibility to type 2 diabetes
2. Identifying the nuclear in nuclear medicine as high benefit
3. Identifying Piwis partners
4. Contagious obesity? Identifying the human adenoviruses that may make us fat
5. Identifying the signatures of protons in water
6. Identifying blood stem cells is a SLAM dunk
7. Identifying the path to infection
8. Interaction of just 2 genes governs coloration patterns in mice
9. Gene regulation, not just genes, is what sets humans apart
10. Study finds gender differences in renal and other genes contributing to blood pressure
11. New databases put wings on search for bipolar risk genes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Identifying genes that contribute low level response alcohol

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: